The treatment of ovarian cancer improved substantially with the introduction of platinum-based chemotherapy in the 1980s. In the 1990s, the results of randomisedcontrolled trials established paclitaxel in combination with a platinum agent as a standard initial chemotherapy for advanced ovarian cancer (1–3). However, over 90% of patients with advanced ovarian cancer will still subsequently die because of clinical failure of chemotherapy, i.e. drug resistance, resulting in an overall 5-year survival of only 30–40%. Clearly, there is a need for more progress in addressing this issue.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer
About this paper
Cite this paper
Tan, D.S.P., Ang, J.E., Kaye, S.B. (2008). Ovarian Cancer: Can We Reverse Drug Resistance?. In: Coukos, G., Berchuck, A., Ozols, R. (eds) Ovarian Cancer. Advances in Experimental Medicine and Biology, vol 622. Springer, New York, NY. https://doi.org/10.1007/978-0-387-68969-2_13
Download citation
DOI: https://doi.org/10.1007/978-0-387-68969-2_13
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-68966-1
Online ISBN: 978-0-387-68969-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)